Clinical trials: Psoriasis Patients
Chronic Plaque Psoriasis
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.
- Trial name
- NCT02570750
- Testing
- QUESTIONNAIRE ON SMOKING HABITS
- Where
- 30 sites in Romania
- Volunteers
- 183 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
- Trial name
- NCT03230292
- Testing
- Bimekizumab
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Rheumatoid Arthritis, Psoriatic Arthritis
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
Rheumatic diseases regroup a variety of disorders affecting the locomotor system including joints, muscles, connective tissues and soft tissues around the joints and bones.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Trial name
- NCT03454932
- Testing
- Blood sampling
- Volunteers
- 30 people
- Sponsor
- Bone Therapeutics S.A
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Pilot observational study to describe the relationship between the smoking status of a psoriatic individual and the success of etanercept therapy in psoriasis treatment
- Trial name
- NCT02192164
- Testing
- smoking questionnaire
- Where
- 8 sites in Hungary
- Volunteers
- 126 people
- Sponsor
- Pfizer
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in…
- Trial name
- NCT05650060
- Testing
- Secukinumab
- Where
- Thailand
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- IXORA-R (NCT03573323)
- Testing
- Ixekizumab, Guselkumab
- Where
- 124 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis, Psoriatic Arthritis
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.
- Trial name
- NCT04614831
- Where
- Switzerland
- Volunteers
- 4,978 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
- Trial name
- NCT04428502
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 127 people
- Sponsor
- Pfizer
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
There is clearly a need for further data on the efficacy of biologic agents in the treatment of nail and scalp psoriasis, especially in the routine clinical setting.
- Trial name
- NCT01202565
- Where
- 73 sites in Czechia, Estonia and 6 more
- Volunteers
- 506 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.
- Trial name
- NCT02547714
- Testing
- Secukinumab (AIN457)
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
This is a retrospective, multi-center observational cohort study. This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed…
- Trial name
- APPRECIATE (NCT02740218)
- Testing
- Patient questionnaire
- Where
- 133 sites in Austria, Croatia and 8 more
- Volunteers
- 610 people
- Sponsor
- Amgen
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriatic Arthritis
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in patients with psoriatic arthritis (PsA).
- Trial name
- PATERA (NCT03598751)
- Testing
- BCD-085
- Where
- 3 sites in Belarus, Russia
- Volunteers
- 194 people
- Sponsor
- Biocad
Plaque Psoriasis
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe…
- Trial name
- NCT06488170
- Testing
- Tildrakizumab
- Where
- 7 sites in Czechia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.